MD Anderson Cancer Center — Clinical Trial Site

168 Registered trials

71 Currently recruiting

Organisation

MD Anderson Cancer Center

Location

Madrid, Spain

Identifier

ORG-100043950

Address

Calle De Arturo Soria Nº 270, 28033, Spain

Departments

-
#7004: Hematología
#93158011: Oncología
#98358011: Oncology
1308: Hematología y Oncología
172408: Hematología
201: Oncología
724001: Oncología
724002:Oncología
724004: Oncología
804: Ensayos Clínicos, Planta 1ª
Breast Cancer Unit
Cancer Center
Cirugía
Department of Oncology
ES011A: Oncología
Haematology
Hematologia
Hematology
Hematology Department
Jefe de Servicio de Hematologia y Hemoterapia
Medical Oncology
Medical Oncology Department
N/A
Oncología
Oncología Médica
oncologia-hematologia
Oncology
Oncology Department
Oncology Physician
Oncology Service
Radiation Oncology
Research Facility
Servicio de Hematología
Servicio de Oncologia
Servicio de Oncología Medica
Unidad de ensayos clínicos
Unidad de Ensayos Clínicos-Oncología
Urology

Clinical trials at this site (168)

Search interface

A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended

2023-508264-29-00 Advanced Renal Cell Carcinoma with Intermediate- or Poo 5 2019-06-11
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended

2023-509059-15-00 Malignant solid tumors: endometrial carcinoma (EC), uro 7 2019-04-30
TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended

2023-509087-20-00 Metastatic Castration-resistant Prostate Cancer 5 2019-04-16
A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended

2024-510985-17-00 First Line Treatment in Subjects with Claudin 18.2 (CLD 4 2019-03-14
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 High Risk Non-muscle invasive bladder cancer 5 2018-11-27
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Pa… Ended

2023-506700-12-00 Locally Advanced or Metastatic Estrogen Receptor−Positi 3 2018-06-18
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended

2024-513521-23-00 Prostate Cancer 5 2015-08-19
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended

2024-511142-39-00 BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cance 5 2013-09-06
A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms Halted

2025-520786-44-00 Myelodysplastic syndromes 7 2025-10-21
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted

2023-505840-20-00 B-Cell Acute Lymphoblastic Leukaemia 9 2024-08-16
A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back aft… Ended

2023-509132-26-00 Refractory/Relapsing B-Cell Malignancies 1 2025-08-08
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated… Ended

2024-511030-12-00 Non-small Cell Lung Cancer (NSCLC) 3 2025-02-03
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended

2023-506866-30-00 HER2 positive or HER2-low metastatic breast cancer 4 2024-08-19
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati… Ended

2023-506882-70-00 Non-small-cell lung cancer 5 2024-08-16
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 recurrent or persistent uterine serous carcinoma 4 2024-05-22
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos… Ended

2023-506038-65-00 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METAS 4 2024-04-15
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended

2023-505145-93-00 Recurrent or Metastatic (R/M) Head and Neck Squamous Ce 7 2024-03-21
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patient… Ended

2024-511007-41-00 Untreated advanced or metastatic non-squamous non-small 9 2023-10-03